{"id":25675,"date":"2025-07-24T08:10:11","date_gmt":"2025-07-24T08:10:11","guid":{"rendered":"https:\/\/clearingtheair.eu\/?p=25675"},"modified":"2025-07-24T08:14:25","modified_gmt":"2025-07-24T08:14:25","slug":"smokeless-nicotine-is-at-the-heart-of-swedens-smoking-decline-says-leading-expert","status":"publish","type":"post","link":"https:\/\/clearingtheair.eu\/en\/post\/smokeless-nicotine-is-at-the-heart-of-swedens-smoking-decline-says-leading-expert\/","title":{"rendered":"Smokeless nicotine is at the heart of Sweden\u2019s smoking decline, says leading expert"},"content":{"rendered":"\n<p><strong>Smokeless nicotine products &#8211; not abstinence &#8211; are driving Sweden\u2019s dramatic drop in smoking, according to a leading clinical psychologist.<\/strong><\/p>\n\n\n\n<p>\u201cSmokeless nicotine is at the heart of Sweden\u2019s smoking decline,\u201d said Karl <a href=\"https:\/\/clearingtheair.eu\/en\/post\/appropriate-for-the-protection-of-public-health-fda-authorises-zyn-nicotine-pouches\/\">Fagerstr\u00f6m<\/a>, a prominent researcher who spent his career developing smoking cessation therapies.<\/p>\n\n\n\n<p>Fagerstr\u00f6m is best known for founding Niconovum in 2000, the company that created the world\u2019s first tobacco-free nicotine pouches. It uses pharmaceutical grade nicotine, the same kind found in patches and gum. The rationale was to create a better way to stop smoking.<\/p>\n\n\n\n<p>Although pouches began as cessation aids, they\u2019ve since gone mainstream, particularly after major tobacco firms entered the market. Reynolds American acquired Niconovum before British American Tobacco took over in 2017.<\/p>\n\n\n\n<p>Fagerstr\u00f6m said public health enthusiasm for smokeless products cooled as the tobacco industry embraced them. This is particularly true in the U.S., one of the few countries where both snus and pouches are legal.<\/p>\n\n\n\n<p>\u201cThe difficulty to accept harm reduction here is also because of the tobacco industry,\u201d Fagerstr\u00f6m said, in an interview with U.S. newspaper Roll Call. \u201cBut when the tobacco industry started to buy up one and each of these small companies, the sentiment changed.\u201d<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>\u2018A safer avenue for nicotine consumption\u2019<\/strong><\/h3>\n\n\n\n<p>Fagerstr\u00f6m argues that quitting smoking shouldn\u2019t be viewed as an all-or-nothing choice, and points to unsuccessful alcohol and illicit drug prohibition efforts.&nbsp;<\/p>\n\n\n\n<p>The watershed to accepting harm reduction, he said, is recognising that the world is unlikely to stop using nicotine altogether and that other options provide a safer avenue for nicotine consumption.<\/p>\n\n\n\n<p>It\u2019s a view shared by Swedish Match, now owned by Philip Morris International (PMI). \u201cWe consume tobacco and nicotine to the same extent [as] any other population. The difference is that we do not die from it to the same extent,\u201d said Patrik Hildingsson, vice president of communications and public affairs.<\/p>\n\n\n\n<p>Sweden restricts smoking in most public places, and cultural norms have shifted. But some public health advocates remain wary of harm reduction. This is largely due to the tobacco industry\u2019s record of misleading the public on the harms of smoking.<\/p>\n\n\n\n<p>\u201cThe problem in Sweden is that although we\u2019ve been very successful in making less people smoke because of getting the information out\u2026 the tobacco industry in Sweden realised that they had a hard time winning the game about smoking,\u201d said Niclas Malmberg, board member of the think tank Tobaksfakta and a former member of Sweden\u2019s parliament.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A promising trend towards harm reduction&nbsp;<\/strong><\/h3>\n\n\n\n<p>There is far more research on snus than on newer pouches, but early findings suggest a promising trend toward harm reduction. Sweden\u2019s public health agency has acknowledged the important role of snus in reducing the country\u2019s smoking rates.<\/p>\n\n\n\n<p>Fagerstr\u00f6m isn\u2019t alone in calling for a shift in approach in the U.S. and other countries to take a similar approach.<\/p>\n\n\n\n<p>In a 2024 editorial for the journal JAMA, former FDA commissioners Scott Gottlieb and Mark McClellan wrote: <\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cFor these currently nicotine-addicted adult smokers, the opportunity to convert to noncombustible products offering nicotine delivery without the combustion-related health risks should be a renewed part of the U.S. public health agenda.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>But bringing harm-reduction products to the U.S. remains a challenge. With costs topping $1.5 million (\u20ac1.28) per product for FDA approval, small players are often locked out.<\/p>\n\n\n\n<p>\u201cThe U.S. is the most closed market in the world, except if you don\u2019t count the ones where it\u2019s banned outright,\u201d said Daniel Wiberg, who runs a business with his son selling nicotine pouches that shield users\u2019 gums.<\/p>\n\n\n\n<p>Larger companies are also pushing for reform. At a recent Capitol Hill briefing, Matt Holman, former FDA Office of Science director and now a top executive at PMI, suggested Congress could streamline reviews by requiring comparisons to existing products. He also called for performance benchmarks to speed up FDA decisions.<\/p>\n\n\n\n<p>Last month, the FDA opened a public comment period on PMI\u2019s Modified Risk applications for Zyn pouches, but nicotine products still can\u2019t be marketed as safer without official approval.<\/p>\n\n\n\n<p>The FDA\u2019s sluggish pace has drawn criticism from lawmakers, with then-Subcommittee Chair Brett Guthrie calling out the agency\u2019s \u201cfailure to authorise tobacco harm reduction products.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Smokeless nicotine products &#8211; not abstinence &#8211; are driving Sweden\u2019s dramatic drop in smoking, according to a leading clinical psychologist. \u201cSmokeless nicotine is at the heart of Sweden\u2019s smoking decline,\u201d said Karl Fagerstr\u00f6m, a prominent researcher who spent his career developing smoking&hellip;<\/p>\n","protected":false},"author":990005,"featured_media":25695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[257],"tags":[183,186,333],"slider":[],"class_list":["post-25675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-harm-reduction","tag-nicotine","tag-sweden"],"_links":{"self":[{"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/posts\/25675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/users\/990005"}],"replies":[{"embeddable":true,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/comments?post=25675"}],"version-history":[{"count":2,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/posts\/25675\/revisions"}],"predecessor-version":[{"id":25683,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/posts\/25675\/revisions\/25683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/media\/25695"}],"wp:attachment":[{"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/media?parent=25675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/categories?post=25675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/tags?post=25675"},{"taxonomy":"slider","embeddable":true,"href":"https:\/\/clearingtheair.eu\/en\/wp-json\/wp\/v2\/slider?post=25675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}